Get Ready to Ride in Style: PSTA Teams Up with Preteckt’s AI to Keep Buses Running Smoothly!

Welcome to the Future of Fleet Maintenance! A Game-Changing Partnership Have you ever experienced the frustration of your vehicle breaking down right when you need it the most? Well, imagine a world where those breakdowns are a thing of the past! Thanks to Preteckt’s groundbreaking technology, that future is closer than you think. Recently, Preteckt…

Read More

Breaking News: FDA Gives Fast Track Designation for Revolutionary Prostate Cancer Treatment!

Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for PSMA-Targeted Radiopharmaceutical for the Treatment of Metastatic Prostate Cancer BEDFORD, Mass. and INDIANAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find,…

Read More

Introducing CyberLink’s Revolutionary People Tracker: Utilizing Cutting-Edge AI Technology for Enhanced Surveillance and Security

Advances in AI Computer Vision and Facial Recognition Technologies People Tracker Solution by CyberLink Corp. TAIPEI, Taiwan–(BUSINESS WIRE)–CyberLink Corp. (5203.TW), a pioneer in AI and facial recognition technologies, today announced the People Tracker solution. Widely used in the fields of surveillance and security, this technology has revolutionized the way we track and identify individuals. With…

Read More

Unveiling the Potential of DT-168: Design Therapeutics to Showcase Promising Preclinical Data for Fuchs Endothelial Corneal Dystrophy Treatment at ARVO 2023

Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule Treatment with DT-168 Eye Drops Reduced Nuclear Foci and Significantly Improved Mis-Splicing In Vitro Company On-track to Submit Investigational New Drug Application for DT-168 in the Second Half of 2023 CARLSBAD, Calif., April 24, 2023 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a…

Read More